ZEPBOUND (tirzepatide) injection, for subcutaneous use: Prescribing information
Clinical trials have demonstrated varying degrees of weight loss depending on the specific agent: liraglutide typically achieves 5-8% weight loss over 56 weeks (SCALE trials), while semaglutide has shown approximately 15% weight loss over 68 weeks (STEP trials)
References Vargason, A
By activating GLP-1, it sends fullness signals to your brain, enabling you to be satisfied with less food
Without standardized third-party testing, buyers cannot verify product purity, dosing accuracy, or contamination
Semaglutide can be used as both a monotherapy and in combination with other medications in ulcerative colitis management, depending on individual patient characteristics, disease severity, and treatment goals